CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Amphastar Pharmaceuticals, Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Amphastar Pharmaceuticals, Inc
11570 6th St
Phone: (909) 980-9484p:909 980-9484 RANCHO CUCAMONGA, CA  91730  United States Ticker: AMPHAMPH
Business Summary
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Operating Officer, Chief Scientist ZipingLuo 75 1/1/2005 1/1/1996
President, Chief Executive Officer, Chief Scientific Officer, Director YongfengZhang 78 4/10/2020 1/1/1996
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International William J.Peters 57 8/4/2022 4/1/2014
7 additional Officers and Directors records available in full report.

Business Names
Business Name
AMPH
Amphastar Nanjing Pharmaceuticals, Inc.
BAQSIMI®
Nanjing Letop Fine Chemistry Co., Ltd.

General Information
Number of Employees: 1,976 (As of 12/31/2025)
Outstanding Shares: 44,092,919 (As of 5/1/2026)
Shareholders: 115
Stock Exchange: NASD
Federal Tax Id: 330702205
Fax Number: (302) 655-5049
Email Address: info@amphastar.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 13, 2026